[1] Sah P, Fitzpatrick MC, Zimmer CF, et al. Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis. Proc Natl Acad Sci U S A 2021; 118: e2109229118. doi: 10.1073/pnas.2109229118 [2] Long B, Carius BM, Chavez S, et al. Clinical update on COVID-19 for the emergency clinician: Presentation and evaluation. Am J Emerg Med 2022; 54: 46−57. doi: 10.1016/j.ajem.2022.01.028 [3] Schulze H, Charles JJ, Trampe N, et al. Cross-sectional analysis of clinical aspects in patients with long-COVID and post-COVID syndrome. Front Neurol 2022; 13: 979152. doi: 10.3389/fneur.2022.979152 [4] Soriano JB, Murthy S, Marshall JC, et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 2022; 22: e102−e107. doi: 10.1016/S1473-3099(21)00703-9 [5] Mohammad KO, Lin A, Rodriguez JBC. Cardiac manifestations of post-acute COVID-19 infection. Curr Cardiol Rep 2022; 24: 1775−1783. doi: 10.1007/s11886-022-01793-3 [6] Gaine S, Devitt P, Coughlan JJ, et al. COVID-19-associated myocarditis presenting as new-onset heart failure and atrial fibrillation. BMJ Case Rep 2021; 14: e244027. doi: 10.1136/bcr-2021-244027 [7]

Zuin M, Rigatelli G, Bilato C, et al. One-Year Risk of Myocarditis After COVID-19 Infection: A Systematic Review and Meta-analysis. Can J Cardiol 2022. DOI: 10.1016/j.cjca.2022.12.003. Published online first: Dec 12, 2022.

[8] Hernandez I, Gabriel N, He M, et al. COVID-19 and anticoagulation for atrial fibrillation: an analysis of US nationwide pharmacy claims data. J Am Heart Assoc 2021; 10: e023235. doi: 10.1161/JAHA.121.023235 [9] Schiavone M, Sozzi FB, Gasperetti A, et al. Clinical management of new-onset atrial fibrillation in COVID-19 patients referred to a tertiary cardiac arrhythmia center after hospital discharge. J Clin Med 2022; 11: 5661. doi: 10.3390/jcm11195661 [10] Carnicelli AP, Hong H, Connolly SJ, et al. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex. Circulation 2022; 145: 242−255. doi: 10.1161/CIRCULATIONAHA.121.056355 [11] Xu B, MacIsaac A. Life-threatening haemorrhagic pericarditis associated with rivaroxaban. Int J Cardiol 2014; 174: e75−e76. doi: 10.1016/j.ijcard.2014.04.151 [12] Rizzi DA, Pedersen SA. Causality in medicine: towards a theory and terminology. Theor Med 1992; 13: 233−254. doi: 10.1007/BF00489201 [13] Huseynov A, Akin I, Duerschmied D, et al. Cardiac Arrhythmias in post-COVID syndrome: prevalence, pathology, diagnosis, and treatment. Viruses 2023; 15: 389. doi: 10.3390/v15020389 [14] Liguori C, Farina D, Vaccher F, et al. Myocarditis: imaging up to date. Radiol Med 2020; 125: 1124−1134. doi: 10.1007/s11547-020-01279-8 [15] Chung MK, Zidar DA, Bristow MR, et al. COVID-19 and cardiovascular disease: from bench to bedside. Circ Res 2021; 128: 1214−1236. doi: 10.1161/CIRCRESAHA.121.317997 [16] Lazzerini PE, Laghi-Pasini F, Boutjdir M, et al. Inflammatory cytokines and cardiac arrhythmias: the lesson from COVID-19. Nat Rev Immunol 2022; 22: 270−272. doi: 10.1038/s41577-022-00714-3 [17] Fujinami RS, von Herrath MG, Christen U, et al. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev 2006; 19: 80−94. doi: 10.1128/CMR.19.1.80-94.2006 [18] Marraki ZE, Bouzhir A, Nguadi J, et al. Post-COVID myocarditis simulating acute coronary syndrome: Case report. Radiol Case Rep 2023; 18: 665−670. doi: 10.1016/j.radcr.2022.11.023 [19] Baksi AJ, Kanaganayagam GS, Prasad SK. Arrhythmias in viral myocarditis and pericarditis. Card Electrophysiol Clin 2015; 7: 269−281. doi: 10.1016/j.ccep.2015.03.009 [20] Imazio M, Trinchero R. Myopericarditis: etiology, management, and prognosis. Int J Cardiol 2008; 127: 17−26. doi: 10.1016/j.ijcard.2007.10.053 [21] Raatikainen P, Lassila R. COVID-19: another reason for anticoagulation in patients with atrial fibrillation. Heart 2022; 108: 902−904. doi: 10.1136/heartjnl-2022-320845 [22] January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64: e1−e76. doi: 10.1016/j.jacc.2014.03.022 [23] Julia S, James U. Direct Oral Anticoagulants: A Quick Guide. Eur Cardiol 2017; 12: 40−45. doi: 10.15420/ecr.2017:11:2 [24] Sheikh AB, Shah I, Sagheer S, et al. Hemopericardium in the Setting of Direct Oral Anticoagulant Use: An Updated Systematic Review. Cardiovasc Revasc Med 2022; 39: 73−83. doi: 10.1016/j.carrev.2021.09.010 [25] Asad ZUA, Ijaz SH, Chaudhary AMD, et al. Hemorrhagic cardiac tamponade associated with apixaban: a case report and systematic review of literature. Cardiovasc Revasc Med 2019; 20: 15−20. doi: 10.1016/j.carrev.2019.04.002 [26] Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239−245. doi: 10.1038/clpt.1981.154 [27]

Fernandez S, Lenoir C, Samer C, et al. Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports. Pharmacol Res Perspect 2020; 8: e00647.

[28]

Shah N, Saleh M, Jyala A, et al. COVID-19-Induced Myopericarditis Leading to Cardiac Tamponade: An Unusual Case Presentation. Cureus 2022; 14: e27158.